文献速递白血病造血干细胞移植与细胞治疗

CPX-351序贯氟达拉滨、阿糖胞苷及粒细胞集落刺激因子治疗儿童复发急性髓系白血病的I/II期研究:儿童肿瘤学组报告

Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
PubMed 文献 · J Clin Oncol · 2020-05-13

AAML1421为I/II期研究,纳入38例复发/难治急性髓系白血病患儿,确定CPX-351的II期推荐剂量为135单位/m²(第1、3、5天),1/6例出现剂量限制性毒性(3级射血分数下降),无毒性死亡;最佳缓解包括完全缓解20例(54%)、血小板部分恢复的完全缓解5例(14%)及血细胞不完全恢复的完全缓解5例(14%),缓解者中29/30(96.7%)接受造血干细胞移植巩固。

要点

  • CPX-351的II期推荐剂量为135单位/m²,第1、3、5天给药。
  • 第1周期≥3级毒性包括发热/中性粒细胞减少(45%)、感染(47%)和皮疹(40%),无毒性死亡。
  • 最佳缓解:完全缓解20例(54%),血小板部分恢复的完全缓解5例(14%),血细胞不完全恢复的完全缓解5例(14%)。

核心结论

  • CPX-351的II期推荐剂量为135单位/m²,第1、3、5天给药,毒性可控且方案治疗有效,缓解率优于既往已发表的北美合作组儿童急性髓系白血病首次复发临床试验。

研究设计与样本

  • AAML1421为I/II期研究,纳入年龄>1岁且≤21岁的复发/难治急性髓系白血病患儿,剂量探索阶段6例,疗效阶段为首次复发者32例。
  • 第1周期评估剂量限制性毒性,最多给予2个周期治疗(第1周期CPX-351;第2周期FLAG方案:氟达拉滨30 mg/m²/剂第1-5天,阿糖胞苷2,000 mg/m²/剂第1-5天,粒细胞集落刺激因子5 µg/kg/剂第1-5天及第15天起至中性粒细胞绝对计数>500/µL),每周期后评估缓解。

主要发现

  • 剂量探索阶段6例中1例出现剂量限制性毒性(3级射血分数下降),II期推荐剂量为135单位/m²(第1、3、5天)。
  • 第1周期≥3级毒性包括发热/中性粒细胞减少45%、感染47%、皮疹40%,无毒性死亡。
  • 最佳缓解包括完全缓解20例(54%)、血小板部分恢复的完全缓解5例(14%)、血细胞不完全恢复的完全缓解5例(14%)。
  • 25例完全缓解/血小板部分恢复的完全缓解者中21例(84%)经流式细胞术检测无可检测残留病。
  • 30例缓解者中29例(96.7%)接受造血干细胞移植巩固,移植前25例中20例(80%)无残留病。

关键数值与推荐

  • II期推荐剂量:CPX-351 135单位/m²,第1、3、5天给药。
  • FLAG方案:氟达拉滨30 mg/m²/剂第1-5天,阿糖胞苷2,000 mg/m²/剂第1-5天,粒细胞集落刺激因子5 µg/kg/剂第1-5天及第15天起至中性粒细胞绝对计数>500/µL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought to determine the recommended phase II dose (RP2D) of CPX-351 and the response rate after up to 2 cycles of therapy. PATIENTS AND METHODS: Children > 1 and ≤ 21 years of age with relapsed/refractory AML were eligible for dose finding; those in first relapse were eligible for the efficacy phase. Dose-limiting toxicity (DLT) assessment occurred during cycle 1. Two cycles of therapy were offered (cycle 1: CPX-351; cycle 2: FLAG [fludarabine 30 mg/m2/dose on days 1-5; cytarabine 2,000 mg/m2/dose on days 1-5; and granulocyte-colony stimulating factor 5 µg/kg/dose, days 1-5 and day 15 through absolute neutrophil count > 500/µL]). Response was assessed after each cycle. RESULTS: Thirty-eight patients enrolled: 6 in the dose-finding phase and 32 in the efficacy phase. During dose finding, 1/6 patients experienced a DLT (grade 3 decrease in ejection fraction). The RP2D was 135 units/m2 on days 1, 3, and 5. Toxicities of grade ≥ 3 during cycle 1 included fever/neutropenia (45%), infection (47%), and rash (40%). There was no toxic mortality. Best responses included 20 complete response (CR; 54%), 5 CR with partial recovery of platelet count (CRp; 14%), and 5 CR with incomplete blood count recovery (14%). Twenty-one of 25 with CR/CRp had no detectable residual disease (RD; 84%) by flow cytometry. Hematopoietic stem cell transplantation (HSCT) was used as consolidation in 29/30 responders (96.7%); 20/25 (80%) had no RD before HSCT. CONCLUSION: The RP2D of CPX-351 is 135 units/m2/dose on days 1, 3, and 5. Toxicity was manageable, and protocol therapy was effective. Response rates are superior to prior published North American cooperative group clinical trials for children with AML in first relapse.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cooper TM, Absalon MJ, Alonzo TA, et al. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020. PMID: 32401633. doi:10.1200/JCO.19.03306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。